Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.64USD
16 Feb 2018
Change (% chg)

$-0.01 (-0.27%)
Prev Close
$3.65
Open
$3.63
Day's High
$3.67
Day's Low
$3.62
Volume
210,226
Avg. Vol
366,315
52-wk High
$4.59
52-wk Low
$2.86

Chart for

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule,... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $950.48
Shares Outstanding(Mil.): 270.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Amarin Prices Public Offering Of American Depositary Shares

* AMARIN PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

30 Jan 2018

BRIEF-Amarin Announces Proposed Public Offering Of American Depositary Shares

* AMARIN ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

29 Jan 2018

BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China

* AMARIN ANNOUNCES COMMENCEMENT OF VASCEPA CLINICAL DEVELOPMENT IN MAINLAND CHINA Source text for Eikon: Further company coverage:

17 Jan 2018

BRIEF-Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​

* AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK

04 Jan 2018

BRIEF-Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study

* AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018

19 Dec 2017

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations

01 Nov 2017

BRIEF-Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

* Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

25 Sep 2017

BRIEF-Amarin names Mark Salyer chief commercial officer

* Amarin appoints Mark W. Salyer to new position of chief commercial officer

13 Sep 2017

Competitors

Earnings vs. Estimates